Edition:
India

Galectin Therapeutics Inc (GALT.OQ)

GALT.OQ on NASDAQ Stock Exchange Capital Market

4.28USD
20 Feb 2018
Change (% chg)

$-0.06 (-1.38%)
Prev Close
$4.34
Open
$4.25
Day's High
$4.68
Day's Low
$4.23
Volume
72,066
Avg. Vol
143,338
52-wk High
$6.73
52-wk Low
$1.29

Latest Key Developments (Source: Significant Developments)

Galectin Therapeutics Says $10 Mln Credit Line From Richard Uihlein Sufficient To Cover Expected Expenditures Into 2019
Wednesday, 20 Dec 2017 

Dec 19 (Reuters) - Galectin Therapeutics Inc ::GALECTIN THERAPEUTICS ANNOUNCES $10 MILLION CREDIT LINE FROM RICHARD E. UIHLEIN SUFFICIENT TO COVER EXPECTED EXPENDITURES INTO 2019.GALECTIN THERAPEUTICS INC - BORROWINGS UNDER CREDIT LINE ARE AT COMPANY'S DISCRETION THROUGH DECEMBER 31, 2018.  Full Article

Galectin Therapeutics Announces Results From Phase 2b NASH-CX Trial Of GR-MD-02
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - Galectin Therapeutics Inc ::GALECTIN THERAPEUTICS ANNOUNCES RESULTS FROM PHASE 2B NASH-CX TRIAL OF ITS PROPRIETARY COMPOUND GR-MD-02.GALECTIN - PHASE 2B TRIAL NASH-CX SHOWED STATISTICALLY SIGNIFICANT RESULTS IN REDUCING PRIMARY ENDPOINT MEASUREMENT OF HVPG VERSUS PLACEBO.GALECTIN - FOR MAJOR SECONDARY ENDPOINT ASSESSMENT OF LIVER BIOPSY, SAW STATISTICALLY SIGNIFICANT EFFECT OF TREATMENT TO IMPROVE HEPATOCYTE BALLOONING.GALECTIN - THERE WAS STATISTICALLY SIGNIFICANT REDUCTION IN DEVELOPMENT OF NEW ESOPHAGEAL VARICES IN PATIENTS WITHOUT VARICES AT BASELINE.GALECTIN-THERE WAS POSITIVE TREND IN TOTAL GROUP,BUT DIFFERENCE DID NOT REACH STATISTICAL SIGNIFICANCE IN REDUCING PRIMARY ENDPOINT MEASUREMENT OF HVPG​‍​.  Full Article

Galectin Therapeutics To Present Results From Phase 2B Nash-Cx Trial On December 5, 2017
Tuesday, 5 Dec 2017 

Dec 4 (Reuters) - Galectin Therapeutics Inc ::GALECTIN THERAPEUTICS TO PRESENT RESULTS FROM PHASE 2B NASH-CX TRIAL ON DECEMBER 5, 2017.  Full Article

Combination Immunotherapy of Pembrolizumab with the Galectin-3 inhibitor gr-md-02 shows promising early results
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Galectin Therapeutics Inc :Combination Immunotherapy of Pembrolizumab with the Galectin-3 inhibitor gr-md-02 shows promising early results in treatment of advanced melanoma from a phase 1b clinical trial.  Full Article

Galectin Therapeutics posts qtrly loss per share $0.13‍​
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Galectin Therapeutics Inc :Galectin Therapeutics Inc - Qtrly loss per share $0.13‍​.Galectin Therapeutics Inc - ‍Top line results of NASH-CX phase 2B clinical trial expected to be announced in early December 2017​.Galectin Therapeutics Inc - ‍Company is funded through february 2018, which is sufficient to report top line data of NASH-CX phase 2B clinical trial​.Galectin Therapeutics - Believes it has sufficient cash to fund currently planned operations and research, development activities through Dec. 31, 2017​.Galectin Therapeutics Inc - ‍As of September 30, 2017, company had $7.0 million of non-restricted cash and cash equivalents​.  Full Article

Galectin Therapeutics Q2 loss per share $0.20
Tuesday, 9 Aug 2016 

Galectin Therapeutics Inc : Q2 loss per share $0.20 . Galectin therapeutics reports second quarter 2016 financial results and provides business update . Q2 earnings per share view $-0.24 -- Thomson Reuters I/B/E/S .Believes it has sufficient cash to fund currently planned operations, research and development activities through june 30, 2017.  Full Article

Galectin Therapeutics quarterly loss per share $0.20
Tuesday, 9 Aug 2016 

Galectin Therapeutics Inc : Believes it has sufficient cash to fund currently planned operations and research, development activities through June 30, 2017 . Quarterly loss per share $0.20 . Quarterly loss per share $0.20 . Top-Line data from Nash-Fx trial in Nash patients with advanced fibrosis expected to be reported by end of Sept - sec filing .Q2 earnings per share view $-0.24 -- Thomson Reuters I/B/E/S.  Full Article

Galectin Therapeutics reports positive mid-stage data on psoriasis drug
Tuesday, 17 May 2016 

Galectin Therapeutics Inc : Drug infusions were well tolerated by patients . Two adverse events were noted, one infiltration of intravenous catheter & one headache during infusion; were mild & transient .Announces Positive Interim Results From Phase 2a Trial With Gr Md-02 in moderate-to-severe plaque psoriasis.  Full Article

Galectin Therapeutics reports Q1 loss $0.24/shr
Tuesday, 10 May 2016 

Galectin Therapeutics Inc : Galectin Therapeutics reports first quarter 2016 financial results and provides business update .Q1 loss per share $0.24.  Full Article

Galectin Therapeutics Inc qtrly loss per share $0.24
Tuesday, 10 May 2016 

Galectin Therapeutics Inc : Galectin Therapeutics Inc qtrly loss per share $0.24 . Believes it has sufficient cash to fund currently planned operations, research and development activities through march 31, 2017 . Q1 earnings per share view $-0.17 -- Thomson Reuters I/B/E/S .Remain on track to report top-line data from 156-patient nash-cx trial in nash patients with cirrhosis by the end of 2017.  Full Article

BRIEF-Galectin Therapeutics Says $10 Mln Credit Line From Richard Uihlein Sufficient To Cover Expected Expenditures Into 2019

* GALECTIN THERAPEUTICS ANNOUNCES $10 MILLION CREDIT LINE FROM RICHARD E. UIHLEIN SUFFICIENT TO COVER EXPECTED EXPENDITURES INTO 2019